Abstract
Interleukin-12 (IL-12) is a potent driver of type 1 immunity. Paradoxically, in autoimmune conditions, including of the CNS, IL-12 reduces inflammation. The underlying mechanism behind these opposing properties and the involved cellular players remain elusive. Here we map IL-12 receptor (IL-12R) expression to NK and T cells as well as neurons and oligodendrocytes. Conditionally ablating the IL-12R across these cell types in adult mice and assessing their susceptibility to experimental autoimmune encephalomyelitis revealed that the neuroprotective role of IL-12 is mediated by neuroectoderm-derived cells, specifically neurons, and not immune cells. In human brain tissue from donors with multiple sclerosis, we observe an IL-12R distribution comparable to mice, suggesting similar mechanisms in mice and humans. Combining flow cytometry, bulk and single-nucleus RNA sequencing, we reveal an IL-12-induced neuroprotective tissue adaption preventing early neurodegeneration and sustaining trophic factor release during neuroinflammation, thereby maintaining CNS integrity in mice.
Original language | English |
---|---|
Pages (from-to) | 1701-1712 |
Number of pages | 12 |
Journal | Nature Neuroscience |
Volume | 26 |
Issue number | 10 |
Early online date | 25 Sept 2023 |
DOIs | |
Publication status | Published - Oct 2023 |
Bibliographical note
We thank L. Robinson from Insight Editing London for paper editing; A. Sethi, S. Marti, M. Lutz, N. Puertas, P. Hähne, A. Fonseca da Silva, R. Lindemann, S. Da Costa Pereira and L. Oberbichler for technical support; H. Rehrauer, L. Opitz, A. Cabral de Gouvea, D. Popovic, Q. Zhang, F. Noe and T. Sykes for technical and computational advice on sequencing experiments; the Center for Microscopy and Image Analysis, University of Zurich (ZMB) and the Functional Genomics Center Zurich (FGCZ) for providing equipment. We thank A. Saab (UZH) for the Plp1 strain. The schematic representations of human MS lesions and neuroectodermal cell types were created with BioRender.com . This work has received funding from the Swiss National Science Foundation (Ambizione grant PZ00P3_193330 to S.M. and 733 310030_170320, 310030_188450 and CRSII5_183478 to B.B.), European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 882424 to B.B.), Research Talent Development Fund zur Förderung des akademischen Nachwuchses (FAN; to S.M.), Forschungskredit Postdoc fellowship University of Zurich grant no. K-41302-11-01 (to S.M.), Dr. Wilhelm Hurka Foundation (to B.B. and S.M.) and the Swiss Multiple Sclerosis Society (to S.M. and F.I.). F.I. received a PhD fellowship from Studienstiftung des deutschen Volkes. CreERAll Science Journal Classification (ASJC) codes
- General Neuroscience